Taskinen M R, Smith U
Department of Medicine, University of Helsinki, Finland.
J Intern Med. 1998 Nov;244(5):361-70. doi: 10.1046/j.1365-2796.1998.00397.x.
Diabetes conveys high risk lipid status for cardiovascular disease (CVD). To target the management of diabetic dyslipidaemia requests the understanding of metabolic basis of diabetic dyslipidaemia and its components. Recent progress has opened new information to direct future lipid lowering intervention trials in type 2 diabetic patients. To reduce substantially the risk for CVD aggressive modification of all known risk factors is warranted on the basis of existing data.
